Clinical trials
Completed Phase 4 trials in Malaysia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
120 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 2 |
| 2003 | 6 |
| 2004 | 5 |
| 2005 | 2 |
| 2006 | 4 |
| 2007 | 6 |
| 2008 | 5 |
| 2009 | 6 |
| 2010 | 1 |
| 2011 | 6 |
| 2012 | 11 |
| 2013 | 9 |
| 2014 | 12 |
| 2015 | 6 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 6 |
| 2019 | 7 |
| 2020 | 4 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 6 |
| 2024 | 3 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 120 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Malaya | 11 |
| Novartis Pharmaceuticals | 8 |
| National University of Malaysia | 7 |
| Boehringer Ingelheim | 6 |
| Novo Nordisk A/S | 6 |
| Pfizer | 5 |
| Universiti Kebangsaan Malaysia Medical Centre | 5 |
| AstraZeneca | 4 |
| GlaxoSmithKline | 4 |
| Hoffmann-La Roche | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus, Type 2 | 15 |
| Diabetes Mellitus | 8 |
| Coronary Artery Disease | 6 |
| Hypertension | 6 |
| Arthritis, Rheumatoid | 5 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Pneumonia | 4 |
| Asthma | 3 |
| Cardiovascular Diseases | 3 |
| Coronary Restenosis | 3 |
Trials
Showing 1 to 25 of 120. Each trial links to its page on Pharma Observatory.
20 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.